<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814916</url>
  </required_header>
  <id_info>
    <org_study_id>DUR001-306</org_study_id>
    <secondary_id>2014-005281-30</secondary_id>
    <nct_id>NCT02814916</nct_id>
  </id_info>
  <brief_title>Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute&#xD;
      bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive),&#xD;
      known or suspected to be caused by susceptible Gram-positive organisms, including&#xD;
      methicillin-resistant strains of Staphylococcus aureus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with abnormal audiologic assessment</measure>
    <time_frame>Baseline to Day 28 (± 2 days)]</time_frame>
    <description>Audiologic testing will be conducted in at least 7 children less than 2 years old (at least 3 of which are neonates) and will include evoked otoacoustic emissions testing, acoustic immittance measures (tympanometry and contra and ipsilateral acoustic reflex thresholds) and (optional) threshold auditory brainstem responses. Patients with an abnormal audiologic assessment at Day 28 (plus or minus 2 days) that exceeds, by a clinically significant margin, any abnormality observed in the Baseline assessment, will be considered to have an abnormal audiologic assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in number of patients with the presence of either Clostridium difficile (CD), vancomycin-resistant enterococci (VRE), or both CD and VRE in bowel flora</measure>
    <time_frame>Baseline to Day 28 (± 2 days)</time_frame>
    <description>Evaluated in patients from birth to &lt; 2 years of age, by performing polymerase chain reaction (PCR) for Clostridium difficile (C diff) and culture for vancomycin-resistant enterococci (VRE) on a stool specimen or rectal swab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Baseline to 48 - 72 hours</time_frame>
    <description>Defined as greater than 20% reduction in lesion size compared to baseline. In patients diagnosed with ABSSSI age birth to &lt; 3 months, clinical response at 48-72 hours post-randomization is defined as cessation of increase in lesion size and decreased erythema or tenderness compared to baseline with no appearance of new lesions. In patients diagnosed with sepsis age birth to &lt; 3 months, clinical response at 48-72 hours post-randomization is defined as improvement of at least one abnormal clinical and laboratory parameter related to sepsis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Cure</measure>
    <time_frame>Baseline and Day 14 (± 2 Days)</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Improvement</measure>
    <time_frame>Baseline and Day 14 (± 2 Days)</time_frame>
    <description>Clinical response of Improvement will be defined as a reduction in severity of two or more, but not all, clinical signs and symptoms of infection, when compared with baseline (patients age 3 months to 17 years and ABSSSI patients age birth to &lt;3 months). In sepsis patients age birth to &lt; 3 months, improvement is defined as reduction in severity of at least one abnormal clinical and laboratory parameter related to sepsis, when compared with baseline. In patients age 3 months to 17 years, no additional antibacterial treatment is required for disease under study. In patients age birth to &lt; 3 months, no rescue antibiotics required after at least 48 hours of start of study treatment. This outcome category will only be used at the EOT evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Failure</measure>
    <time_frame>Baseline and Day 14 (± 2 Days)</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Unknown</measure>
    <time_frame>Baseline and Day 14 (± 2 Days)</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure, Improvement or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Cure</measure>
    <time_frame>Baseline and Day 28 (± 2 Days)</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Failure</measure>
    <time_frame>Baseline and Day 28 (± 2 Days)</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Unknown</measure>
    <time_frame>Baseline and Day 28 (± 2 Days)</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Cure</measure>
    <time_frame>Baseline and Day 54 (± 7 days)</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Failure</measure>
    <time_frame>Baseline and Day 54 (± 7 days)</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Unknown</measure>
    <time_frame>Baseline and Day 54 (± 7 days)</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of baseline pathogen after treatment</measure>
    <time_frame>Baseline to Day 54 (± 7 days)</time_frame>
    <description>Direct demonstration of eradication or persistence of the causative organism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality: For patients age birth to &lt; 3 months, all-cause mortality will be determined at test of cure (TOC) visit</measure>
    <time_frame>Baseline and Day 28 (± 2 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dalbavancin plasma concentration</measure>
    <time_frame>Within 14 (± 2) days of study drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">188</enrollment>
  <condition>Methicillin-Resistant Staphylococcus Aureus</condition>
  <condition>Bacterial Infections</condition>
  <condition>Staphylococcal Skin Infections</condition>
  <arm_group>
    <arm_group_label>Dalbavancin, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Dalbavancin, two doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin single dose</intervention_name>
    <description>Dalbavancin, weight-adjusted dose, up to 1500mg. Intravenous (IV) administration. Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used. Patients age birth to &lt;3 months will only receive the single-dose regimen of dalbavancin; any concomitant antibacterial therapy may be administered in this age group based on local standard of care.</description>
    <arm_group_label>Dalbavancin, single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin two dose</intervention_name>
    <description>Dalbavancin, weight-adjusted dose, up to 1000mg. Intravenous (IV) administration, with second dalbavancin weight-adjusted dose, up to 500mg. Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.</description>
    <arm_group_label>Dalbavancin, two doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Course of either vancomycin not to exceed a total daily dose of 4000 mg;or oxacillin; or flucloxacillin not to exceed a total daily dose of 2000 mg. Intravenous (IV) administration. Possible oral switch after at least 72 hours from oxacillin or flucloxacillin to oral cefadroxil, or from IV vancomycin to oral clindamycin (for MRSA). Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used. Additional comparator drugs may be used, if an alternate comparator regimen is indicated by local susceptibility patterns. No patient age birth to &lt; 3 months will be randomized to the comparator arm.</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patients age 3 months to 17 years (inclusive):&#xD;
&#xD;
          -  Male or female patients 3 months to 17 years (inclusive)&#xD;
&#xD;
          -  A clinical picture compatible with Acute Bacterial Skin and Skin Structure Infections&#xD;
             (ABSSSI) suspected or confirmed to be caused by Gram-positive bacteria, including&#xD;
             Methicillin-resistant Staphylococcus aureus (MRSA).&#xD;
&#xD;
          -  In addition to local signs of ABSSSI, the patient has at least one of the following:&#xD;
&#xD;
          -  Fever, defined as body temperature ≥ 38.4°C (101.2°F) taken orally, ≥ 38.7°C (101.6°F)&#xD;
             tympanically, or ≥ 39°C (102.2°F) rectally (core temperature) OR&#xD;
&#xD;
          -  Leukocytosis (WBC &gt; 10,000 mm3) or leukopenia (WBC &lt; 2,000 mm3) or left shift of &gt;10%&#xD;
             band neutrophils&#xD;
&#xD;
          -  Infection either involving deeper soft tissue or requiring significant surgical&#xD;
             intervention&#xD;
&#xD;
          -  Major cutaneous abscess characterized as a collection of pus within the dermis or&#xD;
             deeper that is accompanied by erythema, edema and/or induration which requires&#xD;
             surgical incision and drainage, and is associated with cellulitis such that the total&#xD;
             affected area involves at least 35 cm2 of erythema, or total affected area of erythema&#xD;
             is at least BSA (m2) x 43.0 (cm2/m2), OR alternatively, involves the central face and&#xD;
             is associated with an area of erythema of at least 15 cm2 b. Surgical site or&#xD;
             traumatic wound infection characterized by purulent drainage with surrounding&#xD;
             erythema, edema and/or induration which occurred within 30 days after the trauma or&#xD;
             surgery and is associated with cellulitis such that: i. the total affected area&#xD;
             involves at least 35 cm2 of erythema, or total affected area of erythema is at least&#xD;
             BSA (m2) x 43.0 (cm2/m2), OR ii. alternatively, involves the central face and is&#xD;
             associated with an affected area of at least 15 cm2 c. Cellulitis, defined as a&#xD;
             diffuse skin infection characterized by spreading areas of erythema, edema and/or&#xD;
             induration and: i. is associated with erythema that involves at least 35 cm2 of&#xD;
             surface area, or surface area of erythema is at least BSA (m2) x 43.0 (cm2/m2), OR ii.&#xD;
             alternatively, cellulitis of the central face that is associated with an affected area&#xD;
             of at least 15 cm2 5. In addition to the requirement for erythema, all patients are&#xD;
             required to have at least two (2) of the following signs of ABSSSI:&#xD;
&#xD;
             a. Purulent drainage/discharge b. Fluctuance c. Heat/localized warmth d. Tenderness to&#xD;
             palpation e. Swelling/induration&#xD;
&#xD;
             • In patients age birth to &lt; 3 months, each patient must meet the following inclusion&#xD;
             criteria to be enrolled in this study.&#xD;
&#xD;
               1. Male or female patients from birth to &lt; 3 months of age, including pre-term&#xD;
                  neonates (gestational age ≥ 32 weeks)&#xD;
&#xD;
               2. A clinical picture compatible with an ABSSSI suspected or confirmed to be caused&#xD;
                  by Gram-positive bacteria, including MRSA.&#xD;
&#xD;
                  OR&#xD;
&#xD;
                  Suspected or confirmed sepsis including any of the following clinical criteria:&#xD;
&#xD;
                  a. Hypothermia (&lt;36°C) OR fever (&gt;38.5°C) b. Bradycardia OR tachycardia OR rhythm&#xD;
                  instability c. Hypotension OR mottled skin OR impaired peripheral perfusion d.&#xD;
                  Petechial rash e. New onset or worsening of apnea episodes OR tachypnea episodes&#xD;
                  OR increased oxygen requirements OR requirement for ventilation support f.&#xD;
                  Feeding intolerance OR poor sucking OR abdominal distension g. Irritability h.&#xD;
                  Lethargy i. Hypotonia&#xD;
&#xD;
               3. In addition, patients must meet at least one of the following laboratory&#xD;
                  criteria:&#xD;
&#xD;
                  a. White blood cell count ≤4.0 × 109/L OR ≥20.0 × 109/L b, Immature to total&#xD;
                  neutrophil ratio &gt;0.2 c. Platelet count ≤100 × 109/L d. C-reactive protein (CRP)&#xD;
                  &gt;15 mg/L OR procalcitonin ≥ 2 ng/mL e. Hyperglycemia OR Hypoglycemia f. Metabolic&#xD;
                  acidosis&#xD;
&#xD;
               4. Infections must be of sufficient severity to merit hospitalization and parenteral&#xD;
                  antibiotic therapy. These infections may include:&#xD;
&#xD;
                    1. Cutaneous or subcutaneous abscess&#xD;
&#xD;
                    2. Surgical site or traumatic wound infection&#xD;
&#xD;
                    3. Cellulitis, Erysipelas&#xD;
&#xD;
                    4. Omphalitis&#xD;
&#xD;
                    5. Impetigo and bullous impetigo&#xD;
&#xD;
                    6. Pustular folliculitis&#xD;
&#xD;
                    7. Scarlet fever&#xD;
&#xD;
                    8. Staphylococcal scalded skin syndrome&#xD;
&#xD;
                    9. Streptococcal toxic shock syndrome&#xD;
&#xD;
                   10. Erythematous based-erosion&#xD;
&#xD;
                   11. Other infections originating in the skin or subcutaneous tissue and&#xD;
                       associated with signs and symptoms of sepsis as defined in Inclusion&#xD;
                       Criterion 2.&#xD;
&#xD;
               5. Patients must be expected to survive with appropriate antibiotic therapy and&#xD;
                  appropriate supportive care throughout the study.&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
               1. Patients age 3 months to 17 years: Clinically significant renal impairment,&#xD;
                  defined as calculated creatinine clearance of less than 30 mL/min. (calculated by&#xD;
                  the Schwartz &quot;bedside&quot; formula). Patients birth to &lt; 3 months of age: Moderate or&#xD;
                  severe renal impairment defined as serum creatinine ≥ 2 times the upper limit of&#xD;
                  normal (× ULN) for age OR urine output &lt; 0.5 mL/kg/h (measured over at least 8&#xD;
                  hours prior to dosing) OR requirement for dialysis.&#xD;
&#xD;
               2. Clinically significant hepatic impairment, defined as serum bilirubin or alkaline&#xD;
                  phosphatase greater than 2 times the upper limits of normal (ULN) for age, and/or&#xD;
                  serum aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than&#xD;
                  3 times the upper limits of normal (ULN) for age.&#xD;
&#xD;
               3. Treatment with an investigational drug within 30 days preceding the first dose of&#xD;
                  study medication.&#xD;
&#xD;
               4. Patients with sustained shock defined as systolic blood pressure &lt; 90 mm Hg in&#xD;
                  children ≥ 10 years old, &lt; 70 mm Hg + [2 x age in years] in children 1 to &lt;10&#xD;
                  years, or &lt; 70 mmHg in infants 3 to &lt;12 months old for more than 2 hours despite&#xD;
                  adequate fluid resuscitation, with evidence of hypoperfusion or need for&#xD;
                  sympathomimetic agents to maintain blood pressure.&#xD;
&#xD;
               5. More than 24 hours of any systemic antibacterial therapy within 96 hours before&#xD;
                  randomization. EXCEPTION: Microbiological or clinical treatment failure with a&#xD;
                  systemic antibiotic other than IV study drug that was administered for at least&#xD;
                  48 hours. Failure must be confirmed by either a microbiological laboratory report&#xD;
                  or documented worsening clinical signs or symptoms.&#xD;
&#xD;
               6. Infection due to an organism known prior to study entry to be resistant to&#xD;
                  dalbavancin (dalbavancin minimum inhibitory concentration (MIC) greater than 0.25&#xD;
                  ug/mL) or vancomycin (vancomycin minimum inhibitory concentration (MIC) greater&#xD;
                  than 2 ug/mL).&#xD;
&#xD;
               7. Patients with necrotizing fasciitis, or deep-seated infections that would require&#xD;
                  &gt; 2 weeks of antibiotics (e.g., endocarditis, osteomyelitis or septic arthritis).&#xD;
&#xD;
               8. Infections caused exclusively by Gram-negative bacteria (without Gram-positive&#xD;
                  bacteria present) and infections caused by fungi, whether alone or in combination&#xD;
                  with a bacterial pathogen.&#xD;
&#xD;
               9. Venous catheter entry site infection.&#xD;
&#xD;
              10. Infections involving diabetic foot ulceration, perirectal abscess or a decubitus&#xD;
                  ulcer.&#xD;
&#xD;
              11. Patient with an infected device, even if the device is removed. Examples include&#xD;
                  infection of: prosthetic cardiac valve, vascular graft, a pacemaker battery pack,&#xD;
                  joint prosthesis, implantable pacemaker or defibrillator, intraaortic balloon&#xD;
                  pump, left ventricular assist device, or a neurosurgical device such as a&#xD;
                  ventricular peritoneal shunt, intra-cranial pressure monitor, or epidural&#xD;
                  catheter.&#xD;
&#xD;
              12. Gram-negative bacteremia, even in the presence of Gram-positive infection or&#xD;
                  Gram-positive bacteremia. Note: If a Gram-negative bacteremia develops during the&#xD;
                  study, or is subsequently found to have been present at Baseline, the patient&#xD;
                  should be removed from study treatment and receive appropriate antibiotic(s) to&#xD;
                  treat the Gram-negative bacteremia.&#xD;
&#xD;
              13. Patients whose skin infection is the result of having sustained full or partial&#xD;
                  thickness burns.&#xD;
&#xD;
              14. Patients age 3 months to 17 years, with uncomplicated skin infections such as&#xD;
                  superficial/simple cellulitis/erysipelas, impetiginous lesion, furuncle, or&#xD;
                  simple abscess that only requires surgical drainage for cure. Patients birth to &lt;&#xD;
                  3 months of age may be enrolled if they have uncomplicated skin infections of&#xD;
                  sufficient severity to require hospitalization and parenteral antibiotic therapy.&#xD;
&#xD;
              15. Patients age 3 months to 17 years: Concomitant condition requiring any antibiotic&#xD;
                  therapy that would interfere with the assessment of study drug for the condition&#xD;
                  under study.&#xD;
&#xD;
              16. Sickle cell anemia&#xD;
&#xD;
              17. Cystic fibrosis&#xD;
&#xD;
              18. Anticipated need of antibiotic therapy for longer than 14 days.&#xD;
&#xD;
              19. Patients who are placed in a hyperbaric chamber as adjunctive therapy for the&#xD;
                  ABSSSI.&#xD;
&#xD;
              20. More than 2 surgical interventions (defined as procedures conducted under sterile&#xD;
                  technique and typically unable to be performed at the bedside) for the skin&#xD;
                  infection, or patients who are expected to require more than 2 such&#xD;
                  interventions.&#xD;
&#xD;
              21. Medical conditions in which chronic inflammation may preclude assessment of&#xD;
                  clinical response to therapy even after successful treatment (e.g., chronic&#xD;
                  stasis dermatitis of the lower extremity).&#xD;
&#xD;
              22. Immunosuppression/immune deficiency, including hematologic malignancy, recent&#xD;
                  bone marrow transplant (in post-transplant hospital stay), absolute neutrophil&#xD;
                  count &lt; 500 cells/mm3, receiving immunosuppressant drugs after organ&#xD;
                  transplantation, receiving oral steroids ≥ 20 mg prednisolone per day (or&#xD;
                  equivalent) for &gt; 14 days prior to enrollment, and known or suspected human&#xD;
                  immunodeficiency virus (HIV) infected patients with a CD4 cell count&lt; 200&#xD;
                  cells/mm3 or with a past or current acquired immunodeficiency syndrome&#xD;
                  (AIDS)-defining condition and unknown CD4 count.&#xD;
&#xD;
              23. Known or suspected hypersensitivity to glycopeptide antibiotics, betalactam&#xD;
                  agents, aztreonam, or cephalosporins.&#xD;
&#xD;
              24. Patients with a rapidly fatal illness, who are not expected to survive for 3&#xD;
                  months.&#xD;
&#xD;
              25. Positive urine (or serum) pregnancy test at screening (post-menarchal females&#xD;
                  only) or after admission (prior to dosing).&#xD;
&#xD;
              26. Pregnant or nursing females; sexually active females of childbearing potential&#xD;
                  who are unwilling or unable to use adequate contraceptive precautions. Female&#xD;
                  patients to have pregnancy testing are those who are at least 10 years old with&#xD;
                  menarche and/or thelarche (beginning of breast development).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ALLERGAN INC.</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>844-663-3742</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama /ID# 237446</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604-3302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Southbay Pharma Research /ID# 235700</name>
      <address>
        <city>La Palma</city>
        <state>California</state>
        <zip>90623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles /ID# 237533</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado /ID# 237622</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital /ID# 237061</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta - Ferry Rd /ID# 237003</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342-1605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center /ID# 234353</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1544</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Childrens Mercy Hosp and Clin /ID# 237800</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Univ Hosp /ID# 237862</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University /ID# 236831</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center /ID# 234315</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705-4410</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Main Campus /ID# 237564</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment ( UMHAT) Sveti Georgi EAD Plovdiv /ID# 235487</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Sveti Georgi /ID# 237026</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Kanev /ID# 237809</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>SHAT Hematologic Diseases /ID# 237915</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Ninos Dr. Roberto del Rio /ID# 235568</name>
      <address>
        <city>Independencia</city>
        <zip>8380418</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardioinfantil /Id# 238041</name>
      <address>
        <city>Bogota</city>
        <state>Cundinamarca</state>
        <zip>111156</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Vic /ID# 238117</name>
      <address>
        <city>Medellin</city>
        <zip>50010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>General Hospital of Athens Ippokratio /ID# 237186</name>
      <address>
        <city>Athens</city>
        <state>Attiki</state>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Papageorgiou General Hospital Thessaloniki /ID# 237505</name>
      <address>
        <city>Stavroupoli (Thessalonikis)</city>
        <state>Thessaloniki</state>
        <zip>55536</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Roosevelt /ID# 235520</name>
      <address>
        <city>Guatemala</city>
        <zip>1011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Centro Medico Infectology Department /ID# 235522</name>
      <address>
        <city>Guatemala</city>
        <zip>1016</zip>
        <country>Guatemala</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Pediatria /ID# 235506</name>
      <address>
        <city>Ciudad De Macxico</city>
        <zip>04530</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Del Niño Dr. José Renán Esquivel /ID# 235572</name>
      <address>
        <city>Panama City</city>
        <zip>0816-00383</zip>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politecnico La Fe /ID# 237086</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Greece</country>
    <country>Guatemala</country>
    <country>Mexico</country>
    <country>Panama</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Argentina</country>
    <country>Belarus</country>
    <country>Georgia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Bacterial Skin and Skin Structure Infection (ABSSSI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Cellulitis</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Skin Diseases, Bacterial</mesh_term>
    <mesh_term>Staphylococcal Skin Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalbavancin</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>For details on when studies are available for sharing, please refer to the link below</ipd_time_frame>
    <ipd_access_criteria>Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/abbvie/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

